Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16846614 | 0.95 | PTGS2 (0.49) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| Piperazine SCHEMBL28754426 | 0.91 | PTGS2 (0.43) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| SCHEMBL27616882 | 0.84 | PTGS2 (0.50) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| SCHEMBL8876620 | 0.81 | PTGS2 (0.51) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| SCHEMBL27918605 | 0.80 | PTGS2 (0.44) | PTGS2EPHX2CYSLTR2CYSLTR1SOAT1 | |
| SCHEMBL1346500 | 0.79 | PTGS2 (0.53) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| SCHEMBL1644440 | 0.79 | SLC6A4 (0.49) | PTGS2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3842830 | 0.79 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3016133 | 0.78 | PTGS2 (0.46) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 | |
| SCHEMBL9171692 | 0.78 | PTGS2 (0.54) | PTGS2EPHX2CYSLTR2CYSLTR1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | SLC6A4, SLC18A2, SLC6A2 | PTGS2 3775/4885EPHX2 3722/4885CYSLTR2 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.